Results 111 to 120 of about 163,785 (367)

Impaired myocardial relaxation with exercise determines peak aerobic exercise capacity in heart failure with preserved ejection fraction [PDF]

, 2017
Background Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome characterized by impaired exercise capacity due to shortness of breath and/or fatigue.
Abbate, Antonio, Arena, Ross, Buckley, Leo, Canada, Justin M., Carbone, Salvatore, Dixon, Dave, Trankle, Cory, Van Tassell, Benjamin   +7 more
core   +2 more sources

Activation of Spinal Astrocyte α2A Adrenoceptors Protects Against Sepsis‐Induced Heart Injury Through Inhibition of GABAergic Neuronal Necroptosis

Advanced Science, EarlyView.
The study in this paper found that activating the α2A receptors of astrocytes in the thoracic spinal cord can reduce the release of inflammatory factors, thereby decreasing the necroptosis of GABAergic neurons and consequently alleviating myocardial injury caused by sepsis.
Ruilin He, Bin Wu, Liuhu Han, Mingde Li, Wenli Guo, Jiajing Fu, Bin Mei, Eric R. Gross, Xuesheng Liu, Yao Lu   +9 more
wiley   +1 more source

Cardiometabolic Phenotype in HFpEF: Insights from Murine Models

Biomedicines
Heart failure with preserved ejection fraction (HFpEF) remains a significant challenge in modern healthcare. It accounts for the majority of heart failure cases and their number worldwide is steadily increasing.
Ekaterina Ogurtsova, Tatiana Arefieva, Anastasiia Filatova, Natalya Radyukhina, Artem Ovchinnikov   +4 more
doaj   +1 more source

Insights into the pulmonary vascular complications of heart failure with preserved ejection fraction [PDF]

, 2019
Pulmonary hypertension in the setting of heart failure with preserved ejection fraction (PH-HFpEF) is a growing public health problem that is increasing in prevalence.
Gladwin, Mark T., Lai, Yen‐Chun, Wang, Longfei   +2 more
core   +1 more source

ER‐phagy Activation by AMFR Attenuates Cardiac Fibrosis Post‐Myocardial Infarction via mTORC1 Pathway

Advanced Science, EarlyView.
By catalyzing FAM134B ubiquitination and activating ER‐phagy, AMFR alleviates progressive fibrosis and cardiac dysfunction by inhibiting the mTORC1 pathway. Consequently, these findings underscore the essential role of AMFR‐driven ER‐phagy in mitigating the progression of fibrotic responses, offering a potential therapeutic target for preventing heart ...
Zhixiang Wang, Kaifan Niu, Wei Liu, Xinyun Wang, Boshen Yang, Taixi Li, Yizhi Chen, Yuanyuan Jin, Yu Chen, Yangyi Lin, Xian Jin   +10 more
wiley   +1 more source

ALKBH5‐Mediated M6A Demethylation of G3BP1 Attenuates Ferroptosis Via Cytoplasmic Retention of YBX1/p53 in Diabetic Myocardial Ischemia‐Reperfusion Injury

Advanced Science, EarlyView.
ALKBH5 promoted G3BP1 expression via m⁶A methylation at sites 142/173. G3BP1 interacts with YBX1 and p53, reducing their nuclear translocation and decreasing p53‐mediated SLC7A11 repression. This inhibites cardiomyocyte ferroptosis and mitigates myocardial damage during diabetic ischemia‐reperfusion injury.
Wenyuan Li, Wei Li, Yan Leng, Heng Xu, Zhongyuan Xia, Yao Wang   +5 more
wiley   +1 more source

Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Background Resistant hypertension is a salt‐retaining condition possibly attributable to inappropriate aldosterone secretion. Methods and Results This study was a secondary analysis of the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure ...
Tetsuro Tsujimoto, Hiroshi Kajio
doaj   +1 more source

Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS‐HF trial

European Journal of Heart Failure
Steroidal mineralocorticoid receptor antagonists (MRAs), spironolactone and eplerenone, are strongly recommended in the treatment of patients with chronic heart failure (HF) with reduced left ventricular ejection fraction (LVEF), but the balance of ...
M. Vaduganathan, B. Claggett, C. Lam, B. Pitt, M. Senni, Sanjiv J. Shah, A. Voors, F. Zannad, A. Desai, P. Jhund, Prabhakar Viswanathan, Antonieta Bomfim Wirtz, Patrick Schloemer, James Lay-Flurrie, J. McMurray, Scott D. Solomon   +15 more
semanticscholar   +1 more source

LncRNA Foxo6os as a Novel “ Scaffold” Mediates MYBPC3 in Combating Pathological Cardiac Hypertrophy and Heart Failure

Advanced Science, EarlyView.
Schematic overview showing that forkhead box O6, opposite strand (Foxo6os) acts as a “scaffold”, directly binding myosin‐binding protein‐C (MYBPC3) and recruiting protein kinase C (PKC‐α) to mediate site‐specific phosphorylation of MYBPC3. This post‐translational modification supports cardiac contraction by regulating L‐type Ca2+ channels, especially ...
Jie Sheng, Qin Lin, Yizhuo Sun, Yilei Meng, Sangyu Hu, Huaming Cao, Fang Lin, Yuping Zhu, Luying Peng, Li Li   +9 more
wiley   +1 more source

Heart failure with preserved left ventricular ejection fraction – clinical perspectives

Annales Academiae Medicae Silesiensis
Heart failure with preserved ejection fraction (HFpEF) is an increasingly recognized subtype of heart failure, particularly affecting older adults and women.
Małgorzata Niemiec, Bartosz Gruchlik, Nicola Dyrek, Jan Niemiec, Bartosz Basiaga, Krzysztof Bednarz, Dorota Piłat, Kinga Czepczor, Maciej Podolski, Katarzyna Mizia-Stec   +9 more
doaj   +1 more source